New 'Alpha' cancer drug enters human testing for Tough-to-Treat prostate cancer
NCT ID NCT07214961
Summary
This is a first-in-human study to test the safety and find the right dose of a new experimental drug called AB001 for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The drug is a type of targeted radiation therapy designed to seek out and destroy prostate cancer cells. The study will enroll about 80 patients to see how their bodies handle the drug and to look for early signs that it might help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BAMF Health
RECRUITINGGrand Rapids, Michigan, 49503, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
United Theranostics
RECRUITINGPrinceton, New Jersey, 08540, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
XCancer
RECRUITINGOmaha, Nebraska, 68130, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.